China-based Jiangsu BioPerfectus Technologies Co., Ltd (SHA: 688399), a leading manufacturer of in vitro diagnostic (IVD) products, has announced that it has received medical device approval from the National Medical Products Administration (NMPA) for its Norovirus nucleic acid detection kit, utilizing the fluorescence PCR method.
Innovative Detection of Norovirus
The newly approved detection kit is designed for the in vitro qualitative detection of Norovirus GI and GII type nucleic acid RNA in fecal samples. This advancement is crucial for enhancing diagnostic capabilities, particularly in identifying Norovirus infections, which are a significant cause of gastroenteritis outbreaks globally.
Enhancing Public Health Responses
With the NMPA approval, Jiangsu BioPerfectus aims to strengthen its position in the IVD market by providing reliable diagnostic solutions. The Norovirus detection kit is expected to play a vital role in public health responses, enabling faster and more accurate identification of Norovirus cases, thereby assisting healthcare providers in managing outbreaks effectively.-Fineline Info & Tech
